Stryker Corporation 10-Qquarter ended 2026-06-30

Executive Summary

Stryker delivered volume-led Q2 growth across both major segments, with sales increasing 9.4% and GAAP net earnings rising 44%. Earnings growth overstated the underlying improvement: a tariff reversal and lower acquisition-related costs boosted comparisons, while H1 adjusted operating margin was broadly flat. Management is concentrating orthopaedic technology around Mako and expanding its vascular portfolio, but weaker U.S. vascular sales and cybersecurity-related production disruption challenge execution. For investors, the opportunity is sustained procedure-driven growth with operating leverage; the key test is whether profitability improves without temporary accounting benefits while cash generation supports acquisitions and debt reduction.

Key Financial Highlights

• Tariff reversal: $158M increased reported operating income, net earnings by $133M and diluted EPS by $0.34; this is not recurring operating improvement. It contributed 260 bp to Q2 gross-margin expansion, versus 70 bp from volume and mix.
• Margin quality: Q2 GAAP operating margin was 25.2%, versus adjusted 27.4%; H1 was 20.6%, versus adjusted 24.4%, broadly flat Y/Y. Manufacturing and supply-chain costs reduced H1 gross margin by 100 bp.
• Capital allocation: H1 acquisition cash payments fell to $459M from $4.81B; dividends were $674M and capital expenditures $368M. Shares outstanding increased from 382.5M to 383.5M, alongside $133M of stock-based compensation.
• Acquisition accounting: goodwill of $19.6B and net other intangible assets of $5.74B explain negative tangible common equity; these assets make acquisition performance consequential to future earnings and book value.

Business Developments

• Portfolio growth: Q2 MedSurg and Neurotechnology revenue reached $3.63B, +9.7%, and Orthopaedics $2.96B, +9.1%. Medical, Endoscopy, and Trauma and Extremities grew at double-digit rates; management expects faster growth in lower-margin MedSurg and Neurotechnology to pressure gross-margin mix.
• Orthopaedic organization: the new Ortho Tech reporting unit combines orthopaedic instruments, Mako and enabling technologies to simplify the customer experience and focus innovation. Q2 Ortho Tech sales grew 10%; the $518M goodwill transfer between segments was a reallocation, not an impairment.
• Vascular expansion: AVS adds a developing intravascular lithotripsy platform for complex peripheral arterial disease. Purchase consideration totaled $706M, including $435M net cash and milestone payments valued at $271M; the preliminary allocation principally reflects in-process R&D.
• Geographic growth: Q2 international sales increased 11% reported and 9.2% in constant currency, versus 8.9% U.S. growth. Currency provided a modest quarterly lift rather than explaining most growth.

Risk Assessment

• Cybersecurity disruption: the incident reported on 3/11/2026 caused idle production time, contributing to manufacturing costs; further disruption could impair shipments and margins.
• Acquisition execution: Inari carries $3.12B of goodwill, while AVS adds development-stage exposure; disappointing commercialization or integration could undermine returns and asset values.
• Vascular weakness: Q2 vascular sales declined 0.7%, including a 6.7% U.S. decline, challenging the growth thesis behind portfolio investment.
• Funding and liquidity: $14.9B of total debt creates refinancing exposure, while acquisitions and dividends compete with debt repayment for cash.
• Product liability and regulation: adverse litigation, recalls or injunctions could require significant payments or restrict sales; self-insured claims may exceed estimates.
• Foreign exchange: exchange rates are Stryker’s largest identified market-risk exposure, affecting international earnings and investment values despite hedging.

This 10-Q lists no risk factors of its own and refers to the annual report. The risks above come from the rest of this filing. Full list: the company's 10-Ks on SEC.

Strategic Outlook and Investor Actionables

Management is betting on integrated orthopaedic technologies and vascular innovation to sustain growth, while cash generation funds acquisitions, dividends and deleveraging. The opportunity is broader customer adoption; the threat is that development costs, operational disruption and unfavorable product mix absorb the growth benefits.

• Ortho Tech adoption: Q2 growth of 10% establishes the starting point. Sustained growth would support the integrated Mako-and-instruments strategy; deceleration would weaken that thesis.
• Vascular recovery: Q2 sales declined 0.7%, despite 12% H1 growth. Renewed growth would support portfolio expansion, including AVS; persistent U.S. declines or acquisition-related write-downs would indicate execution problems.
• Durable earnings and cash: H1 adjusted operating margin was 24.4%, broadly flat, with OCF of $1.84B versus GAAP earnings of $2.02B. Improving margins without tariff benefits and cash keeping pace with earnings would validate operating leverage; stagnant margins or a widening cash shortfall would not.